Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy
PDF (1.9M)
+3 authors
Journal: 2020/June - Journal of Medical Case Reports
PUBMED: 32587886
Abstract:
Cardiac manifestations of COVID-19 include myocarditis, demand ischemia, myocardial infarction and arrhythmias with prothrombotic state being a major underlying pathogenetic mechanism. In this report we present a case of a 57-year-old, otherwise healthy, woman who presented with chest pain and nausea and was found to have an inferior wall ST-elevation myocardial infarction (STEMI) in the setting of an active COVID-19 infection. Angiography revealed tortuous coronary arteries with a 100% right coronary artery occlusion with high thrombus burden and normal left coronary system. In light of the available literature regarding the pro-thrombotic effects of this novel corona virus, we continued full dose anticoagulation with Enoxaparin after the cardiac catheterization and transitioned to rivaroxaban and we also continued the patient on dual antiplatelet therapy prior to discharge.
Keywords: Anticoagulation; COVID-19; Fibrinolysis; Percutaneous Coronary Intervention; STEMI (ST-Elevation Myocardial Infarction); Thrombosis; severe acute respiratory syndrome 2 (SARS-Cov-2).
Open in
PUBMED | Google Scholar | Wikipedia
Relations:
Content
References
(7)
Diseases
(5)
Conditions
(3)
Chemicals
(2)
Organisms
(1)
Processes
(1)
Anatomy
(1)
Similar articles
Articles by the same authors
Discussion board
Am J Med Case Rep 8(9): 262-267
PMID: 32587886

Management of ST-Elevation Myocardial Infarction in the COVID-19 Era: The Role of Thrombosis and Anticoagulation Strategy

Department of Medicine, SUNY Downstate health Sciences University, Brooklyn, NY
Division of Cardiovascular Medicine, SUNY Downstate health Sciences University, Brooklyn, NY
Corresponding author: ude.etatsnwod@enalrafcms
Copyright notice
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

References

  • 1. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020.
  • 2. Guo T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. Epub 3-27–20.
  • 3. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2): 271–280. e278.
  • 4. Wood, Shelley“COVID-19 Linked to 38% Drop in US STEMIs.” TCTMD.com, TCTMD.com, 10 Apr. 2020, .[PubMed][Google Scholar]
  • 5. Recommendations From the Peking Union Medical College Hospital for the Management of Acute Myocardial Infarction During the COVID-19 Outbreak. Eur Heart J. 2020; March 31:
  • 6. Mahmud Ehtisham“ACC, SCAI, ACEP Release Consensus Statement on Management of AMI Patients During COVID-19.” American College of Cardiology, 20 April 2020, .[PubMed][Google Scholar]
  • 7. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. [[PubMed]
  • 8. Fox Sharon, et al“Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans.” medRxiv preprint. [PubMed][Google Scholar]
  • 9. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020.
  • 10. Mega J, Eugene B, Stephen W et al“Rivaroxaban in Patients with a Recent Acute Coronary Syndrome” N Engl J Med 2012; 366: 9–19. [[PubMed][Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.